{"entity":{"id":"ionc102","kind":"drug","name":"IONC102","aka":[],"tldr":"IONC102 is an experimental RNA immunotherapy from iOncologi that is being tested in an early trial in glioblastoma.","summary":"IONC102 is iOncologi's multilamellar RNA nanocomplex paired with AI-optimised, off-the-shelf antigens, which the company says is in a phase 1 trial in glioblastoma. The trial was not matched to a registry record in OnCo, so no cancer link is recorded.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"iOncologi","url":"https://ioncologi.com/"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ioncologi"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"IONC102","modality":"RNA lipid nanoparticle immunotherapy","mechanism":"RNA delivered in multilamellar lipid particles to prime a broad immune response, paired with off-the-shelf tumour antigens, as described by iOncologi.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ionc102/","neighbours":{"company":[{"id":"ioncologi","kind":"company","name":"iOncologi","route":"/companies/ioncologi/"}]}}